Abingdon Health plc (AIM: ABDX) announces a £3.3m placing at a price of 6 pence per share
Abingdon Health plc, a leading international developer, manufacturer and regulatory services provider for rapid diagnostic tests and med-tech, announces that, further to its announcement at 5:04 p.m. on 13 October 2025, it has successfully completed and closed the Placing to raise gross proceeds of £3.3 million.
Zeus Capital Limited is acting as agent for and on behalf of the Company in respect of the Placing. The Placing was undertaken through an accelerated bookbuild process.
- The fundraise will be used to accelerate expansion operations in the USA & to enhance the capital required in new & upcoming revenue-generating projects
- Chris Hand, executive chairman, has agreed to subscribe to 500,000 placing shares
- The fundraising is conditional on shareholder approval of the resolutions to be proposed at a General Meeting on 30 October
- In addition to the placing, the Company is launching a retail offer to raise up to £200,000
Read the full announcement here: https://www.londonstockexchange.com/news-article/ABDX/result-of-placing-and-notice-of-gm/17277463
Dr Chris Hand, Executive Chairman of Abingdon Health plc, commented:
"I am delighted that we can announce the completion of this Fundraising. Our full service CDMO offering and recently established Abingdon Health USA are both resonating well with customers. This investment will allow us to execute larger projects and expand USA manufacturing activities to promote our growth. I would like to thank current shareholders for their tremendous support and welcome new shareholders to the Company."
